{"id":"allovectin-7-dacarbazine","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Vomiting"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL476","moleculeType":"Small molecule","molecularWeight":"182.19"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Allovectin-7 works by stimulating an immune response against telomerase, a protein that is overexpressed in many cancer cells. Dacarbazine, on the other hand, is a alkylating agent that adds an alkyl group to DNA, causing cross-linking and interfering with DNA replication, ultimately leading to cell death.","oneSentence":"Allovectin-7 is a DNA vaccine that targets telomerase, while dacarbazine is a chemotherapy drug that interferes with DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:52.969Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT00395070","phase":"PHASE3","title":"A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma","status":"COMPLETED","sponsor":"Vical","startDate":"2006-10","conditions":"Metastatic Melanoma","enrollment":390},{"nctId":"NCT00003647","phase":"PHASE3","title":"Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"Vical","startDate":"1998-07","conditions":"Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"allovectin-7/dacarbazine","genericName":"allovectin-7/dacarbazine","companyName":"Vical","companyId":"vical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Allovectin-7 is a DNA vaccine that targets telomerase, while dacarbazine is a chemotherapy drug that interferes with DNA replication. Used for Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}